India’s leading electric two-wheeler mobility platform is entering into Electric Bicycle Space with their new product Transil e1. Transil is the B2C vertical of eBikeGo which aims to produce modern, effective and sustainable consumer products and all innovative electric vehicles will be launched under the Transil brand name. The pre-booking of Transil e1 Bicycle will be commenced in a few weeks. The Bicycle will be launched in 3 colours and it will be priced around INR. 44,999.
With Transil, eBikeGo focuses on delivering environmental-friendly solutions of mobility. Electric mobility standards developed and executed by adaptive mobility will allow individuals to not only appreciate the moment but also lean towards a healthier lifestyle. Transil will offer consumers to choose from a variety of fully licensed and insured dependable electric vehicles. Our products are designed to enable a smooth transition from the current transportation model to eco-friendly modes of transportation.
Transil e1 is a fully built e-Bicycle ideal for shorter distances which is powered with a super-finished, unisex steel frame with a single-speed transmission and an efficient & compact Li-Ion battery with smart BMS for better performance. Some of its unique features are high strength and lightweight frame which makes cycling effortless and enjoyable, along with high-quality hardware that makes the system robust. It will help the rider switch to a better and healthier lifestyle. It has low maintenance cost and is a good alternative for individuals commuting less than 40 km. Its affordable and its running cost comes up to less than 5 paise/km. Also, if is safe and has a water-resistant design with speed limiting function.
Transil e1 Bicycle will also adhere to these excellent specifications such as, Hub Motor with BLDC, 250 W, and an advanced battery- BMS – Li-Ion, 36V-5.2AH, temperature monitoring and control, over current protection, Smart Algorithm for Precision Charge Control, High-Efficiency Sine-wave Motor Controller and a rugged Water-Resistant System. It can be charged with a smart charger that has an Auto Cut-off Function and allows portable Battery- Desk Charging and On-Board Charging. Transil e1 has got a User Interface with Compact LED Smart Display and its Per Charge Range is 20+ to 40+ KMs.
Some other specification of Transil e1 are:
Its USB Port is on the Battery only, and its charging time is 2-2.5 hours with an ideal electricity consumption of 0.18 Units per charge (5 paise per km). Power Mode of the Bicycle is Pedal Assist. There is an optional Cruise Mode, Walk Mode, and Throttle which is also Optional. It has got a distinct frame size with High Strength Steel. Its Wheel is Double Walled Alloy Rims, 27.5”. It has got a Single Speed with a Speed Ratio of 3.4. Transil e1 Tyre is 27.5*1.95 and it’s a high-performance tyre. It is also equipped with High-Performance Disc Brakes. Its efficient suspension offers a smoother ride and the saddle is quick release and its adjustable.
“We are extremely delighted and excited to announce the launch of Transil e1, our latest innovation in the fitness category. We are entering into the Smart Electric Bicycle market with the launch of our very 1st Electric Bicycle. We are optimistic that we will receive positive feedback from the consumers and that this product will help the users achieve a sustainable and healthier lifestyle.” said Dr. Irfan Khan, Founder & CEO of eBikeGo.
Cycling is a beneficial and much recommended aerobic activity, which means that your blood vessels, heart and lungs all get a workout. You will breathe deeper, perspire and experience increased body temperature, which will generally improve overall fitness level. The main health benefit of regular cycling includes increased cardiovascular fitness and core workout. Many researchers have studied the relationship between cancer and exercise, especially cancers like colon and breast cancer. Research has shown that if you cycle, the chance of bowel cancer becomes minimal. Some research and evidence suggest that regular cycling reduces the risk of breast cancer.
